NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.99 -0.07 (-3.40 %)
(As of 08/19/2018 07:38 AM ET)
Previous Close$1.99
Today's Range$1.95 - $2.1050
52-Week Range$0.93 - $2.88
Volume276,754 shs
Average Volume513,699 shs
Market Capitalization$118.87 million
P/E Ratio-3.83
Dividend YieldN/A
Beta1.01
Eyepoint Pharmaceuticals logoEyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Debt-to-Equity Ratio1.57
Current Ratio0.83
Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio-3.83
Forward P/E Ratio-4.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.54 million
Price / Sales14.26
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book5.85

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-18,480,000.00
Net Margins-843.54%
Return on Equity-246.01%
Return on Assets-103.22%

Miscellaneous

Employees22
Outstanding Shares54,030,000
Market Cap$118.87 million

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) issued its earnings results on Tuesday, May, 8th. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.02. The firm earned $0.93 million during the quarter, compared to analysts' expectations of $0.69 million. Eyepoint Pharmaceuticals had a negative net margin of 843.54% and a negative return on equity of 246.01%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Eyepoint Pharmaceuticals.

What price target have analysts set for EYPT?

4 brokerages have issued 12 month target prices for Eyepoint Pharmaceuticals' shares. Their predictions range from $3.00 to $10.00. On average, they anticipate Eyepoint Pharmaceuticals' stock price to reach $5.75 in the next year. This suggests a possible upside of 188.9% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (8/16/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks. Our price target is derived from a market value of $245M for EyePoint, which includes a discounted cash flow-based asset value of $265M that includes DEXYCU, YUTIQ, and royalties from 15% discount rate and 2% terminal growth rate. Probability of success assigned to YUTIQ is 90%." (6/26/2018)

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a increase in short interest in July. As of July 13th, there was short interest totalling 1,318,536 shares, an increase of 39.0% from the June 29th total of 948,858 shares. Based on an average daily trading volume, of 208,186 shares, the short-interest ratio is currently 6.3 days. Approximately 5.0% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Who are some of Eyepoint Pharmaceuticals' key competitors?

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
  • Mr. Leonard S. Ross, VP of Fin., Chief Accounting Officer & Principal Financial Officer (Age 68)
  • Dr. Dario A. Paggiarino M.D., VP & Chief Medical Officer (Age 61)
  • Mr. Marty Nazzaro, Sr. VP of Operations
  • Dr. Anna Kluczewska B.D.Sc., CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

News stories about EYPT stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eyepoint Pharmaceuticals earned a coverage optimism score of 0.12 on Accern's scale. They also gave media coverage about the company an impact score of 47.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Eyepoint Pharmaceuticals.

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.08%), BlackRock Inc. (0.27%), Bard Associates Inc. (0.17%), Essex Investment Management Co. LLC (0.15%), Creative Planning (0.14%) and California Public Employees Retirement System (0.12%). Company insiders that own Eyepoint Pharmaceuticals stock include Ew Healthcare Partners, LP and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

Which major investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Bard Associates Inc., Essex Investment Management Co. LLC, Creative Planning, California Public Employees Retirement System and FineMark National Bank & Trust. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Ew Healthcare Partners, LP and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $1.99.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $118.87 million and generates $7.54 million in revenue each year. The company earns $-18,480,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Eyepoint Pharmaceuticals employs 22 workers across the globe.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]


MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.